LB217 / L-Base - LARVOL DELTA

LBAS announced two new drugs, ’LB217’, at the American Association for Cancer Research (AACR) (Maekyung Media Group) - "The company explained that when 'LB217' was administered to an animal model (PDX) transplanted with Tarceva (Erlotinib)-resistant patient-derived non-small cell lung cancer, it showed tumor growth inhibitory effect by reducing autophagy in tumor cells. In addition, an animal model (CDX) of acquired resistance to Tagrisso (Osimertinib), a standard treatment for EGFR-mutated non-small cell lung cancer, was established and LB217 combined showed anticancer efficacy....It said it plans to enter phase 1 clinical trials in the first half of next year with the goal of submitting an IND in Europe."

New trial • Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology